Abbott gains as Baird issues new Outperform on growth outlook
Seeking Alpha ·
Shares of Abbott Laboratories ( ABT ) gained on Wednesday after Baird initiated coverage with an Outperform rating and a $121 price target, citing a stable growth trajectory for the MedTech company driven by a slew of upcoming catalysts.
DYAX Investor Sentiment
Bullish (Long) 37% · Bearish (Short) 63%
463 participants
Related News
- The Financial Select Sector SPDR Premium Income Fund declares monthly distribution of $0.2221
- Interactive Brokers' daily revenue trades rise 53% Y/Y, 6% M/M in June
- Bending Spoons rallies more than 10% in its IPO debut
- Lockheed Martin raised to Buy at Citi; Karman Holdings on positive catalyst watch
- The Materials Select Sector SPDR Premium Income Fund declares monthly distribution of $0.3519
- NETSTREIT leads most-shorted REIT stocks above $2B; JAN sees fewer bets